Innate Immunity Hemorrhagic fever viruses
先天免疫 出血热病毒
基本信息
- 批准号:8233435
- 负责人:
- 金额:$ 46.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2014-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistArenavirusCD14 geneCellsCessation of lifeContainmentCytoplasmic ReceptorsDevelopmentDiseaseDoctor of MedicineEbola virusFilovirusFrankfurt-Marburg Syndrome VirusGene ExpressionGenerationsGenesHost DefenseHumanIRF1 geneImmuneImmune responseImmune systemImmunityIn VitroInfectionInflammationInflammatoryInflammatory Response PathwayInterferon Type IInterferonsKnockout MiceLeadLymphocytic choriomeningitis virusMammalsMediatingMolecularMorbidity - disease rateMusNatural ImmunityNew EnglandPathogenesisPathway AnalysisPathway interactionsPatternPharmaceutical PreparationsPlasmidsPreclinical Drug EvaluationProductionProteinsRNA HelicaseRNA SequencesRegulationResearch Project GrantsRoleSatellite VirusesScreening procedureSeriesSigns and SymptomsSpecificityStructureTLR2 geneTLR6 geneTherapeuticToll-like receptorsViralViral GenesViral Hemorrhagic FeversVirusVirus Diseasesacquired immunityanalogbasebiodefensecell typecytokinedrug productionhemorrhagic fever virusin vivomortalitymouse modelnovel strategiesnovel vaccinespathogenpreventreceptorresearch studyresponsesmall moleculetime useviral RNA
项目摘要
NERCE Project 17: Innate immunity hemorrhagic fever viruses, Robert W. Finberg, M.D., UMass
The innate immune response to hemorrhagic fever viruses determines the early morbidity and mortality
associated with these illnesses. This is a consequence of both induction of host inflammatory cytokines by
the virus, as well as the initial host defense against the virus which includes the production of type 1
interferons (IFN) that prevent viruses from replicating. Our initial series of experiments defined the Toll Like
Receptor (TLR) responses to hemorrhagic fever viruses, focusing on Lymphocytic Choriomeningitis Virus
(LCMV) as a prototypic arenavirus. By using human cells transfected with CD14 and TLR2 and knockout
mice, we were able to demonstrate that the LCMV specific inflammatory cytokine response is mediated
through TLR2, TLR6, and CD14. Screening for small molecules that inhibited LCMV-mediated activation of
NFkB, defined a subset of compounds that may be suitable for preventing TLR2 mediated viral disease by
blocking the induction of inflammatory cytokines ("cytokine storm") associated with many lethal viral
infections.
Our studies of the responses of mouse and human cells to the arenavirus LCMV, and two filoviruses that
cause hemorrhagic fever, namely Ebola and Marburg, reveal that these viruses cause a rapid induction of
inflammatory cytokines in host cells. We plan to use the compounds we have identified as a result of our
screen, in human cells and in mouse models challenged with different hemorrhagic fever to define the
mechanisms of action of these small molecules and determine if they can prevent the "cytokine storm". Initial
virus containment in mammals is dependent upon the induction of type 1 IFN, which is commonly mediated
through cytoplasmic RNA helicases termed RIG-l-like receptors. In this project we will define the genes and
pathways involved in the induction of IFN by hemorrhagic fever viruses and search for small molecules that
might augment that response. In addition we will investigate host genes directly or indirectly modulated by
infection with these viruses and the effects of the small molecules obtained through our screens on
expression of these genes
NERCE项目17:先天免疫性出血热病毒,罗伯特W。芬伯格,医学博士,麻省大学
对出血热病毒的天然免疫应答决定了早期发病率和死亡率
与这些疾病有关。这是由炎症因子诱导宿主炎性细胞因子引起的结果。
病毒,以及针对病毒的初始宿主防御,包括1型的产生,
干扰素(IFN),阻止病毒复制。我们最初的一系列实验定义了Toll Like
淋巴细胞脉络丛脑膜炎病毒对出血热病毒的TLR反应
(LCMV)作为原型沙粒病毒。通过使用用CD 14和TLR 2转染并敲除的人细胞,
在小鼠中,我们能够证明LCMV特异性炎症细胞因子应答是由
TLR 2、TLR 6和CD 14。筛选抑制LCMV介导的活化的小分子,
NFkB定义了可适用于通过以下方式预防TLR 2介导的病毒性疾病的化合物的子集:
阻断与许多致死性病毒相关的炎性细胞因子(“细胞因子风暴”)的诱导,
感染.
我们研究了小鼠和人类细胞对沙粒病毒LCMV和两种丝状病毒的反应,
引起出血热,即埃博拉病毒和马尔堡,揭示这些病毒引起快速诱导
宿主细胞中的炎性细胞因子。我们计划使用我们已经确定的化合物作为我们的结果,
筛选,在人类细胞和小鼠模型中挑战不同的出血热,以确定
这些小分子的作用机制,并确定它们是否可以防止“细胞因子风暴”。初始
哺乳动物中的病毒遏制依赖于1型IFN的诱导,
通过称为RIG-1样受体的细胞质RNA解旋酶。在这个项目中,我们将定义基因,
参与出血热病毒诱导IFN的途径,并寻找
可能会增加这种反应。此外,我们还将研究直接或间接受
这些病毒的感染以及通过我们的筛选获得的小分子对
这些基因的表达
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert William Finberg其他文献
Robert William Finberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert William Finberg', 18)}}的其他基金
International Immunocompromised Host Society's 19th International Symposium on Infections in the Immunocompromised Host
国际免疫低下宿主协会第十九届国际免疫低下宿主感染研讨会
- 批准号:
9260163 - 财政年份:2016
- 资助金额:
$ 46.31万 - 项目类别:
18th International Symposium on Infections in the Immunocompromised Host
第18届免疫低下宿主感染国际研讨会
- 批准号:
8720337 - 财政年份:2014
- 资助金额:
$ 46.31万 - 项目类别:
17th International Symposium on Infections in the Immunocompromised Host
第十七届免疫低下宿主感染国际研讨会
- 批准号:
8330069 - 财政年份:2012
- 资助金额:
$ 46.31万 - 项目类别:
16th Symposium on Infections in the Immunocompromised Host
第16届免疫低下宿主感染研讨会
- 批准号:
7994945 - 财政年份:2010
- 资助金额:
$ 46.31万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 46.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 46.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 46.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




